Abexinostat Shows Promise for B Cell Lymphoma
Abexinostat, a novel pan-histone deacetylase inhibitor, is emerging as a promising therapeutic agent for patients with relapsed or refractory B ...
Abexinostat, a novel pan-histone deacetylase inhibitor, is emerging as a promising therapeutic agent for patients with relapsed or refractory B ...
In a groundbreaking study recently published in BMC Cancer, researchers have unveiled significant abnormalities in the proportions and functional dynamics ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine